Table 1 Clinical and demographic characteristics of the cohort
Not on Anticoagulation | On anticoagulation | p value | |
|---|---|---|---|
Total number of patients | 828 | 120 | |
Age (years) | < 0.0001 | ||
Mean (SD) | 62.0 (13.9) | 70.5 (11.6) | |
Range | 20.4–94.2 | 31.7–94.6 | |
Sex | 0.50 | ||
Female | 372 (44.9) | 50 (41.7) | |
Male | 456 (55.1) | 70 (58.3) | |
ECOG | 0.0001 | ||
0 | 447 (54.0) | 43 (35.8) | |
1 | 290 (35.0) | 54 (45.0) | |
≥ 2 | 60 (7.2) | 20 (16.7) | |
Unknown | 31 (3.7) | 3 (2.5) | |
Primary tumor | < 0.0001 | ||
Melanoma | 417 (50.4) | 48 (40.0) | |
Lung | 139 (16.8) | 40 (33.3) | |
Other | 272 (32.9) | 32 (26.7) | |
Stage | 0.56 | ||
III | 149 (18.0) | 19 (15.8) | |
IV | 679 (82.0) | 101 (84.2) | |
Treatment regimen | 0.002 | ||
Anti-CTLA-4 | 166 (20.0) | 9 (7.4) | |
Anti-PD-1 or Anti-PD-L1 | 497 (60.0) | 93 (77.5) | |
Anti-PD-1 + Anti-CTLA-4 | 165 (19.9) | 18 (15.0) | |
Treatment line | 0.75 | ||
First | 632 (76.3) | 90 (75.0) | |
Non-first | 196 (23.7) | 30 (25.0) | |
Immunotherapy alone or in combination with other therapy | 0.19 | ||
Alone | 632 (76.3) | 85 (70.8) | |
With other therapy | 196 (23.7) | 35 (29.2) | |
Alive status | 0.11 | ||
Alive | 381 (46.0) | 46 (38.3) | |
Deceased | 447 (54.0) | 74 (61.7) |